Highlights ProtoKinetix, Incorporated

Equities

PKTX

US7437221002

Delayed OTC Markets Other stock markets 10:41:41 2024-04-30 am EDT			5-day change	1st Jan Change
0.0169 ^USD	-0.59%		-9.14%	-11.05%

Mar. 29	ProtoKinetix, Incorporated announced a financing transaction	CI
Mar. 20	ProtoKinetix, Incorporated Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ProtoKinetix, Incorporated Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 20	CI
ProtoKinetix, Incorporated Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-18	CI
ProtoKinetix, Incorporated Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-07-14	CI
ProtoKinetix, Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-02	CI
ProtoKinetix, Incorporated Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-10-31	CI
ProtoKinetix, Incorporated Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-07-29	CI
ProtoKinetix, Incorporated Completes Phase 1 Clinical Trials for the Treatment of Type 1 Diabetes in Islet Cell Transplants	22-07-20	CI
ProtoKinetix, Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-10	CI
ProtoKinetix, Incorporated Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-10	CI
Protokinetix, Incorporated Announces Selection of Aagp? Candidate Formulations for Treatment of Dry Eye Disease	21-11-23	CI
ProtoKinetix, Incorporated Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-12	CI
Protokinetix, Incorporated Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-07-28	CI
ProtoKinetix and IQVIA Partners to Support Development of AAGP® Product in the Treatment of Ocular Conditions	21-05-12	CI
ProtoKinetix, Incorporated Announces the Resumption of Phase 1B Clinical Trials for the Use of AAGP Treated Islet Cells in the Treatment of Type 1 Diabetes	21-04-22	CI
Protokinetix, Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2021	21-04-16	CI
Protokinetix, Incorporated Reports Earnings Results for the Full Year Ended December 31, 2020	21-03-05	CI
Protokinetix, Incorporated Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-10-16	CI
Protokinetix Aagp® Restores Vision in Blind Test Subjects	20-09-15	CI
Amendments to ProtoKinetix AAGP® Protocol for Continuation of Phase 1 Human Trials by the University of Alberta Submitted to Health Canada	20-07-13	CI
Protokinetix, Incorporated Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-07-10	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights ProtoKinetix, Incorporated

Equities

PKTX

US7437221002

Highlights

Filters